Sangamo Therapeutics
SGMO
SGMO
196 hedge funds and large institutions have $477M invested in Sangamo Therapeutics in 2022 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 67 increasing their positions, 46 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
196
Holders Change
+9
Holders Change %
+4.81%
% of All Funds
3.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
67
Reduced
46
Closed
23
Calls
$2.45M
Puts
$1.97M
Net Calls
+$478K
Net Calls Change
-$539K
Top Buyers
| 1 |
APM
1
Avidity Partners Management
Dallas,
Texas
|
$11.6M |
| 2 |
2
Nuveen Asset Management
Chicago,
Illinois
|
$16.4M |
| 3 |
3
BlackRock
New York
|
$69.9M |
| 4 |
4
Vanguard Group
Malvern,
Pennsylvania
|
$62.4M |
| 5 |
WA
5
Wasatch Advisors
Salt Lake City,
Utah
|
$64.3M |
Top Sellers
| 1 |
CC
1
Casdin Capital
New York
|
$0 |
| 2 |
2
State Street
Boston,
Massachusetts
|
$34.1M |
| 3 |
3
Millennium Management
New York
|
$3.06M |
| 4 |
4
Federated Hermes
Pittsburgh,
Pennsylvania
|
$1.64M |
| 5 |
5
Morgan Stanley
New York
|
$5.36M |
